Zacks Investment Research Lowers Trillium Therapeutics Inc. (TRIL) to Hold
According to Zacks, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada. “
Other analysts have also recently issued reports about the stock. Cowen and Company reaffirmed a buy rating on shares of Trillium Therapeutics in a report on Sunday, June 12th. Leerink Swann reissued an outperform rating and set a $20.00 target price on shares of Trillium Therapeutics in a report on Monday, August 15th. Oppenheimer Holdings Inc. reissued an outperform rating and set a $32.00 target price on shares of Trillium Therapeutics in a report on Thursday, May 19th. Finally, Ladenburg Thalmann assumed coverage on shares of Trillium Therapeutics in a report on Wednesday, August 3rd. They set a buy rating and a $18.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and an average price target of $22.75.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 14.71 on Friday. The stock’s market cap is $114.94 million. The stock has a 50 day moving average of $12.37 and a 200 day moving average of $10.38. Trillium Therapeutics has a one year low of $6.62 and a one year high of $16.99.
Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in Trillium Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 25,478 shares of the company’s stock valued at $236,000 after buying an additional 1,380 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Trillium Therapeutics during the first quarter valued at approximately $100,000. Sabby Management LLC purchased a new position in Trillium Therapeutics during the first quarter valued at approximately $131,000. K2 Principal Fund L.P. purchased a new position in Trillium Therapeutics during the second quarter valued at approximately $131,000. Finally, Point72 Asset Management L.P. raised its position in Trillium Therapeutics by 8.6% in the second quarter. Point72 Asset Management L.P. now owns 369,300 shares of the company’s stock valued at $3,316,000 after buying an additional 29,300 shares in the last quarter. 39.34% of the stock is currently owned by institutional investors.
Trillium Therapeutics Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.